Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Br J Radiol ; 92(1104): 20190473, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31386554

RESUMO

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis which can have a broad range of clinical and radiological presentations. Typically, ECD affects multiple organ systems, with skeletal involvement present in almost all ECD patients and cardiothoracic manifestations in more than half. Cardiac and thoracic involvement contributes significantly to morbidity and mortality in affected patients and may have prognostic implications. The diagnosis of ECD can be challenging due to its rarity and similarity to other systemic disease processes. Although the diagnosis can be suggested on imaging, histopathology and immunohistochemistry are required for confirmation. We describe the multimodal imaging features of mediastinal, cardiac, pleural and lung parenchymal ECD. This review identifies the most common radiological manifestations of cardiac and thoracic ECD on contrast-enhanced CT, fluorine18-fludeoxyglucose positron emission tomography/CT and cardiac MRI, and highlights the role of these cross-sectional techniques in disease diagnosis.


Assuntos
Doença de Erdheim-Chester/diagnóstico por imagem , Cardiopatias/diagnóstico por imagem , Pneumopatias/diagnóstico por imagem , Doenças do Mediastino/diagnóstico por imagem , Imagem Multimodal/métodos , Meios de Contraste , Doença de Erdheim-Chester/complicações , Fluordesoxiglucose F18 , Cardiopatias/etiologia , Humanos , Pneumopatias/etiologia , Imageamento por Ressonância Magnética , Doenças do Mediastino/etiologia , Doenças Pleurais/diagnóstico por imagem , Doenças Pleurais/etiologia , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X/métodos
2.
J Nucl Med ; 57 Suppl 1: 53S-9S, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26834103

RESUMO

The success of breast cancer therapy is ultimately defined by clinical endpoints such as survival. It is valuable to have biomarkers that can predict the most efficacious therapies or measure response to therapy early in the course of treatment. Molecular imaging has a promising role in complementing and overcoming some of the limitations of traditional biomarkers by providing the ability to perform noninvasive, repeatable whole-body assessments. The potential advantages of imaging biomarkers are obvious and initial clinical studies have been promising, but proof of clinical utility still requires prospective multicenter clinical trials.


Assuntos
Biomarcadores Tumorais , Neoplasias da Mama/diagnóstico por imagem , Imagem Molecular/métodos , Feminino , Humanos , Tomografia por Emissão de Pósitrons/métodos , Tomografia Computadorizada de Emissão de Fóton Único/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA